Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1
Agarwal P. et al, (2025), Nature
Genome-wide association study of somatic GATA1s mutations in newborns with Down Syndrome.
Li Y. et al, (2025), Blood Adv
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Hosseini A. et al, (2025), Nature
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Daver NG. et al, (2025), Blood Journal
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner JF. et al, (2025), Blood
Genome-wide association studies of Down syndrome associated congenital heart defects
Feldman ER. et al, (2024)
Risk Stratification in Older Intensively Treated Patients With AML.
Versluis J. et al, (2024), J Clin Oncol
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Aksöz M. et al, (2024), Sci Immunol, 9
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.
Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA. et al, (2024), Cell Stem Cell
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Risueño A. et al, (2024), Leukemia Research, 140
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk